

MEETING OF PHARMACISTS SPECIALIZING IN NEPHROLOGY IN QUÉBEC
Lévis Centre des Congrès, Lévis (Québec) | Friday, October 4, 2024 From 9 :00 to 12 :00

*** Note: THERE IS NO SIMULTANEOUS TRANSLATION FOR THIS EVENT ***

9 :00	Arrival of participants (registration) and breakfast	Foyer 200
9 :30	Opening remarks	Room 201
9 :40	“GOUT AND CKD: WHAT TO DO? HOW TO DO IT? WHEN TO DO IT?” <i>(Lecture in French)</i>	Ms. Marjolaine Giroux
10 :30	Question period	
10 :40	Health break	Foyer 200
10 :55	“ALTERED DRUG DISPOSITION IN KIDNEY DISEASE: THE ROLE OF NONRENAL ELIMINATION”	Dr. Thomas D. Nolin
11 :45	Question period	
11 :55	Closing words	
12 :00	Lunch	Room 200

This program receives unrestricted educational grants from pharmaceutical companies Amgen Canada and Novo Nordisk Canada without any regards to the choice of speakers, topics, choice of members of the scientific committee.

We also offer our thanks to Amgen Canada as exhibitor.

TITLE: “GOUT AND CKD: WHAT TO DO? HOW TO DO IT? WHEN TO DO IT?” *(Lecture in French)*

SPEAKER: Ms. Marjolaine Giroux, PharmD, M.Sc

LEARNING OBJECTIVES

1. To discuss the pathogenesis and prevalence of gout, in the presence of chronic kidney disease.
2. To describe the impact of gout and its deleterious consequences for the CKD clientele.
3. To select an appropriate therapeutic strategy for the treatment for acute manifestations of gout.
4. To integrate a useful preventive plan for the care of CKD patients suffering from gout.
5. To explore controversial aspects of the management of gout in this context.

TITLE: “ALTERED DRUG DISPOSITION IN KIDNEY DISEASE: THE ROLE OF NONRENAL ELIMINATION”

SPEAKER: Dr. Thomas D. Nolin, PharmD, PhD, FCCP, FCP, FASN

LEARNING OBJECTIVES

1. To analyze the impact of CKD on the metabolism and elimination of drug therapies, in relation to renal and non renal clearance.
2. To discuss clinical and or experimental data on this topic.
3. To explore recommendations of FDA and Health Canada to pharmaceutical companies regarding their elaboration of drug monographs, more specifically in the presence of CKD.